Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: Benefits and limits

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 327-332

  de Francesco, Vincenzo ^a   Zullo, Angelo ^b   Ierardi, Enzo ^a   Giorgio, Floriana ^a   Perna, Federico ^c   Hassan, Cesare ^b   Morini, Sergio ^b   Panella, Carmine ^a   Vaira, Dino ^c  

^a UNIVERSITY OF FOGGIA   (Italy)

^b NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bacterial culture; Etest; H. pylori; Real time PCR

Indexed keywords

CLARITHROMYCIN; PLACEBO;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPEPSIA; ERADICATION THERAPY; FEMALE; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PEPTIC ULCER; PHENOTYPE; POINT MUTATION; REAL TIME POLYMERASE CHAIN REACTION; STRAIN DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; UREA BREATH TEST;

EID: 77950213810     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp445     Document Type: Article

References (34)

1. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84.
2. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 985-1001.
3. Best LM, Haldane DJ, Keelan M et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother 2003; 47: 3138-44.
4. Marais A, Monteiro L, Occhialini A et al. Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut 1999; 44: 463-7.
5. van Doorn LJ, Debets-Ossenkopp YJ, Marais A et al. Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrob Agents Chemother 1999; 43: 1779-82.
6. Oleastro M, Ménard A, Santos A et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 2003; 4: 397-402.
7. Morris JM, Reasonover AL, Bruce MG et al. Evaluation of seaFAST, a rapid fluorescent in situ hybridization test, for detection of Helicobacter pylori and resistance to clarithromycin in paraffin-embedded biopsy sections. J Clin Microbiol 2005; 43: 3494-6.
8. Liu M, Douthwaite S. Activity of the ketolide telithromycin is refractory to Erm monomethylation of bacterial rRNA. Antimicrob Agents Chemother 2002; 46: 1629-33.
9. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003; 51: 9-11.
10. Mamelli L, Prouzet-Mauléon V, Page's JM et al. Molecular basis of macrolide resistance in Campylobacter: role of efflux pumps and target mutations. J Antimicrob Chemother 2005; 56: 491-7.
11. Zullo A, Hassan C, Lorenzetti R et al. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003; 35: 357-61.
12. Savarino V, Zentilin P, Pivari M et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 893-900.
13. Pilotto A, Rassu M, Leandro G et al. GISU: prevalence of Helicobacter pylori resistance to antibiotics in North-east Italy: a multicentre study. Dig Liver Dis 2000; 32: 763-8.
14. Schwartz H, Krause R, Sahba B et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol 1998; 93: 584-90.
15. Chisholm SA, Owen RJ. Application of polymerase chain reaction-based assays for rapid identification and antibiotic resistance screening of Helicobacter pylori in gastric biopsies. Diagn Microbiol Infect Dis 2008; 61: 67-71.
16. Matteo MJ, Granados G, Olmos M et al. Helicobacter pylori amoxicillin heteroresistance due to point mutations in PBP-1A in isogenic isolates. J Antimicrob Chemother 2008; 61: 474-7.
17. Burucoa C, Garnier M, Silvain C et al. Quadruplex real-time PCR assay using allele-specific scorpion primers for detection of mutations conferring clarithromycin resistance to Helicobacter pylori. J Clin Microbiol 2008; 46: 2320-6.
18. Yilmaz O, Demiray E, Tumer S et al. Detection of Helicobacter pylori and determination of clarithromycin susceptibility using formalin-fixed, paraffin-embedded gastric biopsy specimens by fluorescence in situ hybridization. Helicobacter 2007; 12: 136-41.
19. Caristo E, Parola A, Rapa A et al. Clarithromycin resistance of Helicobacter pylori strains isolated from children' gastric antrum and fundus as assessed by fluorescent in-situ hybridization and culture on four-sector agar plates. Helicobacter 2008; 13: 557-63.
20. De Francesco V, Margiotta M, Zullo A et al. Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. Aliment Pharmacol Ther 2006; 23: 429-35.
21. Wueppenhorst N, Stueger HP, Kist M et al. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother 2009; 63: 648-53.
22. De Francesco V, Margiotta M, Zullo A et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007; 59: 783-5.
23. Owen RJ. Molecular testing for antibiotic resistance in Helicobacter pylori. Gut 2002; 50: 285-8.
24. van Doorn LJ, Glupczynski Y, Kusters JG et al. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother 2001; 45: 1500-4.
25. Versalovic J, Osato MS, Spakovsky K et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 1997; 40: 283-6.
26. De Francesco V, Zullo A, Ierardi E et al. The A2143G point mutation of clarithromycin resistance affects Helicobacter pylori eradication. J Clin Gastroenterol 2009; 43: 386.
27. De Francesco V, Margiotta M, Zullo A et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144: 94-100.
28. Vaira D, Zullo A, Vakil N et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-63.
29. Gerard CJ, Olsson K, Ramanathan R et al. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res 1998; 58: 3957-64.
30. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003; 35: 541-5.
31. Broutet N, Tchamgoué S, Pereira E et al. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99-109.
32. De Francesco V, Zullo A, Margiotta M et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004; 19: 407-14.
33. Lai YC, Yang JC, Huang SH. Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. World J Gastroenterol 2004; 10: 991-4.
34. Abdullahi M, Annibale B, Capoccia D et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008; 18: 1450-4.